Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma

Table 1 Clinical and hematological characteristics of SMZL ± VL patients

Clinical stage	n(%)
I E A+B	4 (13.3)
II A+B	0
III A+B	0
IV A+B	24 (80.0)
V A+B	2 (6.7)
Spleen-specific data	Range	Mean
US length of spleen (cm)	6-32	22.72
US width of spleen (cm)	7-18	10.00
CT length of spleen (cm)	7-27	22.00
CT width of spleen (cm)	6-17	10.00
Spleen weight after surgery (g)	50-8000	2236
Spleen infiltration: nodular vs diffuse	18 (60.0) vs 12 (40.0)
Hb (g/L)	79-131	110
Anemia (Hb < 100 g/L)	27 (90.0)
Leukocytosis (WBC > 10 × 109/L)	10 (33.3)
Leukocytopenia (WBC < 4 × 109/L)	9 (30.0)
Neutrocytopenia (Ne < 1.5 × 109/L)	16 (53.3)
Lymphocytosis (Ly > 5 × 109/L)	17 (56.7)
Thrombocytopenia (Plt < 150 × 109/L)	18 (60.0)
Thrombocytosis (Plt > 400 × 109/L)	5 (16.7)
Serum paraprotein (determined)	23 (76.7)
IgG lambda (found)	1 (3.3)
LDH elevated (> 320 U/L)	8 (26.7)
β-2M elevated (> 1.8 μg/L)	25 (83.3)

Hb: Hemoglobin; WBC: White blood cell; Ne: Neutrophil granulocyte; Ly: Lymphocyte; Plt: Platelet; LDH: Lactate dehydrogenase; β-2M: β-2-microglobulin.

Table 2 Results of Cox regression method and significance of compared factors of treatment outcome in our patients

Variables	Score	df	P
Gender	0.244	1	0.621
Age	0.657	1	0.418
Time from the onset of B symptoms to treatment	13.906	10	0.177
CS	0.557	2	0.757
Spleen infiltration (nodular vs diffuse)	0.009	1	0.923
Mode of treatment	0.089	1	0.900